PURPOSE: A greater understanding of the biology of tumor recurrence should improve adjuvant treatment decision making. We conducted a validation study of the 12-gene recurrence score (RS), a quantitative assay integrating stromal response and cell cycle gene expression, in tumor specimens from patients enrolled onto Cancer and Leukemia Group B (CALGB) 9581. PATIENTS AND METHODS: CALGB 9581 randomly assigned 1,713 patients with stage II colon cancer to treatment withedrecolomab or observation and found no survival difference. The analysis reported here included all patients with available tissue and recurrence (n = 162) and a random (approximately 1:3) selection of nonrecurring patients. RS was assessed in 690 formalin-fixed paraffin-embedded tumor samples with quantitative reverse transcriptase polymerase chain reaction by using prespecified genes and a previously validated algorithm. Association of RS and recurrence was analyzed by weighted Cox proportional hazards regression. RESULTS: Continuous RS was significantly associated with risk of recurrence (P = .013) as was mismatch repair (MMR) gene deficiency (P = .044). In multivariate analyses, RS was the strongest predictor of recurrence (P = .004), independent of T stage, MMR, number of nodes examined, grade, and lymphovascular invasion. In T3 MMR-intact (MMR-I) patients, prespecified low and high RS groups had average 5-year recurrence risks of 13% (95% CI, 10% to 16%) and 21% (95% CI, 16% to 26%), respectively. CONCLUSION: The 12-gene RS predicts recurrence in stage II colon cancer in CALGB 9581. This is consistent with the importance of stromal response and cell cycle gene expression in colon tumor recurrence. RS appears to be most discerning for patients with T3 MMR-I tumors, although markers such as grade and lymphovascular invasion did not add value in this subset of patients.
RCT Entities:
PURPOSE: A greater understanding of the biology of tumor recurrence should improve adjuvant treatment decision making. We conducted a validation study of the 12-gene recurrence score (RS), a quantitative assay integrating stromal response and cell cycle gene expression, in tumor specimens from patients enrolled onto Cancer and Leukemia Group B (CALGB) 9581. PATIENTS AND METHODS: CALGB 9581 randomly assigned 1,713 patients with stage II colon cancer to treatment with edrecolomab or observation and found no survival difference. The analysis reported here included all patients with available tissue and recurrence (n = 162) and a random (approximately 1:3) selection of nonrecurring patients. RS was assessed in 690 formalin-fixed paraffin-embedded tumor samples with quantitative reverse transcriptase polymerase chain reaction by using prespecified genes and a previously validated algorithm. Association of RS and recurrence was analyzed by weighted Cox proportional hazards regression. RESULTS: Continuous RS was significantly associated with risk of recurrence (P = .013) as was mismatch repair (MMR) gene deficiency (P = .044). In multivariate analyses, RS was the strongest predictor of recurrence (P = .004), independent of T stage, MMR, number of nodes examined, grade, and lymphovascular invasion. In T3 MMR-intact (MMR-I) patients, prespecified low and high RS groups had average 5-year recurrence risks of 13% (95% CI, 10% to 16%) and 21% (95% CI, 16% to 26%), respectively. CONCLUSION: The 12-gene RS predicts recurrence in stage II colon cancer in CALGB 9581. This is consistent with the importance of stromal response and cell cycle gene expression in colon tumor recurrence. RS appears to be most discerning for patients with T3 MMR-I tumors, although markers such as grade and lymphovascular invasion did not add value in this subset of patients.
Authors: Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark Journal: N Engl J Med Date: 2004-12-10 Impact factor: 91.245
Authors: Andrew M Scott; Greg Wiseman; Sydney Welt; Alex Adjei; Fook-Thean Lee; Wendie Hopkins; Chaitan R Divgi; Lorelei H Hanson; Paul Mitchell; Denise N Gansen; Steven M Larson; James N Ingle; Eric W Hoffman; Paul Tanswell; Gerd Ritter; Leonard S Cohen; Peter Bette; Lisa Arvay; Andree Amelsberg; Dan Vlock; Wolfgang J Rettig; Lloyd J Old Journal: Clin Cancer Res Date: 2003-05 Impact factor: 12.531
Authors: S Welt; C R Divgi; A M Scott; P Garin-Chesa; R D Finn; M Graham; E A Carswell; A Cohen; S M Larson; L J Old Journal: J Clin Oncol Date: 1994-06 Impact factor: 44.544
Authors: Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger Journal: N Engl J Med Date: 2003-07-17 Impact factor: 91.245
Authors: Megan M Garrity; Lawrence J Burgart; Michelle R Mahoney; Harold E Windschitl; Muhammad Salim; Martin Wiesenfeld; James E Krook; John C Michalak; Richard M Goldberg; Michael J O'Connell; Alfred F Furth; Daniel J Sargent; Linda M Murphy; Eunice Hill; Darren L Riehle; Cecelia H Meyers; Thomas E Witzig Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544
Authors: David H Berger; Christine A O'Mahony; Hongmiao Sheng; Jinyi Shao; Daniel Albo; Raymond N DuBois; R Daniel Beauchamp Journal: Surgery Date: 2003-05 Impact factor: 3.982
Authors: Jonathan D Cheng; Roland L Dunbrack; Matthildi Valianou; André Rogatko; R Katherine Alpaugh; Louis M Weiner Journal: Cancer Res Date: 2002-08-15 Impact factor: 12.701
Authors: Carmen J Allegra; Soon Paik; Linda H Colangelo; Allyson L Parr; Ilan Kirsch; George Kim; Pamela Klein; Patrick G Johnston; Norman Wolmark; H Samuel Wieand Journal: J Clin Oncol Date: 2003-01-15 Impact factor: 44.544
Authors: Donna Niedzwiecki; Wendy L Frankel; Alan P Venook; Xing Ye; Paula N Friedman; Richard M Goldberg; Robert J Mayer; Thomas Anthony Colacchio; Jude Marie Mulligan; Timothy S Davison; Eamonn O'Brien; Peter Kerr; Patrick G Johnston; Richard D Kennedy; D Paul Harkin; Richard L Schilsky; Monica M Bertagnolli; Robert S Warren; Federico Innocenti Journal: J Clin Oncol Date: 2016-07-18 Impact factor: 44.544
Authors: P García-Alfonso; J García-Foncillas; R Salazar; P Pérez-Segura; R García-Carbonero; E Musulén-Palet; M Cuatrecasas; S Landolfi; S Ramón Y Cajal; S Navarro Journal: Clin Transl Oncol Date: 2014-11-06 Impact factor: 3.405
Authors: Tao Fu; Emmanouil P Pappou; Angela A Guzzetta; Marilia de Freitas Calmon; Lifeng Sun; Alexander Herrera; Fan Li; Christopher L Wolfgang; Stephen B Baylin; Christine A Iacobuzio-Donahue; Weidong Tong; Nita Ahuja Journal: Ann Surg Date: 2016-02 Impact factor: 12.969